Introduction

Cytosor 500 mg delivers potent cytarabine therapy for patients battling leukemia. This specialized injection formulation targets cancerous cells with precision, offering hope to those diagnosed with various forms of leukemia. Manufactured by Eskayef Pharmaceuticals and supplied by Orio Pharma, Cytosor represents a crucial component in modern hematological cancer treatment protocols.

Powerful Anti-Leukemic Action

Cytarabine works specifically during the S-phase of the cell cycle, effectively inhibiting DNA synthesis in rapidly dividing cancer cells. This targeted approach disrupts cancer cell replication while also providing:

• Antiviral activity
• Immunosuppressant effects
• Focused action against leukemic cells

Versatile Clinical Applications

Cytosor 500 mg has proven efficacy in multiple leukemia-related conditions, including:

• Leukaemic meningitis: Protecting the central nervous system from leukemic infiltration
• Acute leukemias: For both induction therapy (achieving initial remission) and maintenance therapy (sustaining remission)

Flexible Administration Options

Healthcare providers can administer Cytosor through multiple routes depending on the clinical scenario:

Intrathecal Administration (Adult):

• For leukaemic meningitis: 5-75 mg/m² or 30-100 mg every 2-7 days to once daily for 4-5 days
• For lymphomatous meningitis: 50 mg every 2 weeks for 5 doses, then every 4 weeks for 5 doses

Parenteral Administration (Adult):

• Monotherapy: 200 mg/m² daily by continuous IV infusion for 5 days, repeated at approximately 2-week intervals
• Combination therapy: 100 mg/m² twice daily by rapid IV injection or 100 mg/m² daily by continuous IV infusion for 7 days
• Maintenance therapy: 1-1.5 mg/kg once or twice weekly via IV or subcutaneous injection

Clinical Considerations for Optimal Use

Reconstitution Guidelines:

• Intravenous administration: Reconstitute with bacteriostatic water for injection (standard-dose), then further dilute in 250-1,000 ml NaCl 0.9% or dextrose 5% in water for infusion
• Intrathecal administration: Reconstitute with preservative-free NaCl 0.9%, further dilute with Elliot’s B solution, NaCl 0.9%, or lactated Ringer’s injection to preferred final volume (up to 12 ml)

Important Drug Interactions:

• May reduce efficacy of 5-fluorocytosine, digoxin, and gentamicin
• Increased risk of neurotoxicity when combined with other cytotoxic agents (intrathecal)

Contraindications:

• Active meningeal infection

Safety Profile and Monitoring

As with all potent cytotoxic medications, Cytosor requires careful monitoring for potential side effects, which may include:

• Gastrointestinal effects (nausea, vomiting, diarrhea, oral/anal inflammation)
• Hematological effects (thrombocytopenia)
• Neurological effects (headache, weakness, confusion)
• Other effects (fever, rash, hepatic dysfunction)

Special Precautions:

• Previous drug-induced bone marrow suppression
• Renal or hepatic impairment
• Pregnancy (Category D) and lactation

Managing Overdose Situations

In the event of overdose, patients may experience:

• Irreversible CNS toxicity
• Severe arachnoiditis including encephalopathy
• Potentially life-threatening complications

Immediate management includes:

• Cessation of therapy
• Treatment of bone marrow depression (whole blood/platelet transfusions, antibiotics)
• Supportive care to maintain vital functions

Proper Storage for Maximum Efficacy

To maintain Cytosor’s potency:

• IV/SC formulations: Store between 15-25°C
• Intrathecal formulations: Store between 2-8°C
• Avoid freezing all formulations

Why Choose Cytosor from Orio Pharma?

As a trusted oncology medication supplier, Orio Pharma ensures:

• High-quality products manufactured by Eskayef Pharmaceuticals
• Rigorous quality control meeting international standards
• Worldwide delivery within 3-7 working days
• Compassionate support throughout the treatment journey

Cytosor 500 mg represents a cornerstone therapy in the battle against leukemia, delivered with Orio Pharma’s commitment to excellence and patient care.